Bayer AG is putting more heft behind its cell and gene therapy R&D portfolio by paying $40m upfront to Mammoth Biosciences to use its in vivo CRISPR-based gene-editing technology to develop therapies for five undisclosed indications, with an initial focus on liver-targeted diseases.
“Bringing together Mammoth’s novel CRISPR systems with our existing gene augmentation and our induced pluripotent stem cell (iPSC) platforms will allow us to unleash the full potential of our cell and gene therapy
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?